Autoimmune Diseases  >>  GSK239512  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GSK239512 / GSK
NCT01772199: Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Completed
2
131
Canada, Europe, RoW
GSK239512, Placebo
GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
09/14
09/14

Download Options